Sugi Predict

Sugi Predict / Compounds / SCHEMBL366771

SCHEMBL366771

SCHEMBL366771

NC(CO)(Cc1ccccc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.62
▸ HIF1A Q16665 1/20 0.62
▸ ARG1 P05089 2/20 0.57
▸ ARG2 P78540 2/20 0.57
▸ SLC6A2 P23975 1/20 0.47
▸ TAAR1 Q96RJ0 1/20 0.47
▸ BLM P54132 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ FDPS P14324 1/20 0.41
▸ CYP1A2 P05177 3/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ CES1 P23141 2/20 0.40
▸ CES2 O00748 1/20 0.40
▸ AKR1B1 P15121 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7924236 1.00 SMN1; SMN2 (0.62) SMN1; SMN2HIF1AARG1ARG2SLC6A2
SCHEMBL366770 1.00 SMN1; SMN2 (0.62) SMN1; SMN2HIF1AARG1ARG2SLC6A2
SCHEMBL8351006 0.90 SMN1; SMN2 (0.69) SMN1; SMN2HIF1AARG1ARG2SLC6A2
SCHEMBL7235580 0.88 SMN1; SMN2 (0.53) SMN1; SMN2HIF1AARG1ARG2SLC6A2
SCHEMBL7235584 0.88 SMN1; SMN2 (0.53) SMN1; SMN2HIF1AARG1ARG2SLC6A2
SCHEMBL3117439 0.85 BLM (0.61) SMN1; SMN2HIF1AARG1ARG2BLM
SCHEMBL10778604 0.85 BLM (0.61) SMN1; SMN2HIF1AARG1ARG2BLM
SCHEMBL3117431 0.85 BLM (0.61) SMN1; SMN2HIF1AARG1ARG2BLM
SCHEMBL22190022 0.84 SMN1; SMN2 (0.62) SMN1; SMN2HIF1AARG1ARG2SLC6A2
SCHEMBL6533420 0.82 SMN1; SMN2 (0.60) SMN1; SMN2HIF1AARG1ARG2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109219592-A Benzyl phenylate analog derivative and its preparation method and pharmaceutical composition and purposes 中国医学科学院药物研究所 2019-01-15 — — CN claimed
CN-107417572-A Benzyl phenylate analog derivative and its preparation method and pharmaceutical composition and purposes 中国医学科学院药物研究所 2017-12-01 — — CN claimed
EP-2239335-B1 PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS AJINOMOTO KK (JP) 2013-02-27 — — EP claimed
US-8372607-B2 Method for producing serine derivative and protein used for the same AJINOMOTO CO., INC. (JP) 2013-02-12 — — US claimed
US-20100317068-A1 METHOD FOR PRODUCING SERINE DERIVATIVE AND PROTEIN USED FOR THE SAME AJINOMOTO CO., INC. (JP) 2010-12-16 — — US claimed
EP-2239335-A1 PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS Ajinomoto Co., Inc. (JP) 2010-10-13 — — EP claimed
CN-109219592-A Benzyl phenylate analog derivative and its preparation method and pharmaceutical composition and purposes 中国医学科学院药物研究所 2019-01-15 — — CN disclosed
CN-107417572-A Benzyl phenylate analog derivative and its preparation method and pharmaceutical composition and purposes 中国医学科学院药物研究所 2017-12-01 — — CN disclosed
CN-101367794-B Preparation method for quinazoline derivants and medical uses thereof SHANGHAI HENGRUI PHARM CO LTD 2013-07-10 — — CN disclosed
EP-2593471-A1 CYCLOTETRAPEPTIDES WITH PRO-ANGIOGENIC PROPERTIES GENETADI Biotech, S.L. (ES) 2013-05-22 — — EP disclosed
EP-2239335-B1 PROCESS FOR PRODUCTION OF SERINE DERIVATIVE, AND PROTEIN FOR USE IN THE PROCESS AJINOMOTO KK (JP) 2013-02-27 — — EP disclosed
US-8372607-B2 Method for producing serine derivative and protein used for the same AJINOMOTO CO., INC. (JP) 2013-02-12 — — US disclosed
WO-2012007562-A1 CYCLOTETRAPEPTIDES WITH PRO-ANGIOGENIC PROPERTIES GENETADI BIOTECH, S.L. (ES) 2012-01-19 — — WO disclosed
US-7348448-B2 Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease MERCK & CO., INC. (US) 2008-03-25 — — US disclosed
EP-1864995-A1 BETA-LACTAMIC RGD CYCLOPEPTIDES CONTAINING GAMMA TURNS UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) 2007-12-12 — — EP disclosed
WO-2005004803-A2 PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2005-01-20 — — WO disclosed
EP-0906900-B1 A process for preparing optically active 2-hydroxy-methyl-3-phenylpropionic acid AJINOMOTO KK (JP) 2002-01-23 — — EP disclosed
US-6028217-A CHEMICAL INTERMEDIATE FOR RENIN INHIBITOR OR ENKEPHALINASE ENZYME INHIBITOR AJINOMOTO CO., INC. (JP) 2000-02-22 — — US disclosed
EP-0906900-A1 A process for preparing optically active 2-hydroxy-methyl-3-phenylpropionic acid Ajinomoto Co., Inc. (JP) 1999-04-07 — — EP disclosed
CN-1036769-A The method for preparing Cephem Derivative and intermediate thereof EISAI CO LTD (JP) 1989-11-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317068-A1 METHOD FOR PRODUCING SERINE DERIVATIVE AND PROTEIN USED FOR THE SAME SPR, AMD1, DAO SMN1; SMN2 3287/4885HIF1A 3004/4885ARG1 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.